Quest Diagnostics

dgx

Ticker: DGX

Purchased: 31 Oct 2016

Cost basis: $81.29

Current Portfolio Status: Hold

Dividend Reinvestment: N

Dividends paid quarterly in Jan, Apr, Jul, Oct

Shares held on account at Motif

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company offers clinical testing services, such as routine testing, gene-based and esoteric testing, and drugs-of-abuse testing, as well as anatomic pathology services, and related services and insights; risk assessment services for life insurers, healthcare providers, and others; and central laboratory testing for clinical trials. It also develops, manufactures, and markets diagnostic products, including Care360 HER, a healthcare information technology product that allows doctors to electronically create, manage, and distribute patient encounter notes, as well as for patient communication through a patient portal; and ChartMaxx, an enterprise content management system for hospitals, which enables clinical and business workflows to clients. The company provides its diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Focus Diagnostics, Athena Diagnostics, ExamOne, Solstas, and Summit Health brands to patients, physicians, hospitals, accountable care organizations, integrated delivery networks, health plans, employers, and others through a network of laboratories, patient service centers, phlebotomists in physician offices, and other facilities. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Madison, New Jersey.

Reason For Holding: Zika virus diagnostics